GLPG2222 clinical trials
Also written ABBV-2222 and Galicaftor.
- studies test it
- 8
- open now
- 0
- in phase 3
- 0
- first study started
- 2016
How each study uses GLPG2222 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2017 (3)
| Year | Studies |
|---|---|
| 2016 | 2 |
| 2017 | 3 |
| 2019 | 1 |
| 2021 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 0
Often tested with
Tested in the same studies.
Navocaftor (4) · GLPG-2737 (1) · GLPG-2451 (1) · ABBV-576 (1) · ABBV-119 (1)
Studies
Open first, then newest update. How each study uses GLPG2222 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/Navocaftor/ABBV-119 or Galicaftor/Navocaftor/ABBV-576 Combination Therapies in Adult Participants With Cystic FibrosisTerminatedPhase 2AbbVieNCT04853368Written as Galicaftor
- A Phase 2 Study of ABBV-3067 Alone and in Combination With ABBV-2222CompletedPhase 2AbbVieNCT03969888Written as ABBV-2222
- A Study to Assess How Food Affects the Safety and Pharmacokinetics of Galicaftor and NavocaftorCompletedPhase 1AbbVieNCT05538585Written as Galicaftor
- A Study to Evaluate Multiple Doses of GLPG2222 in Adult Subjects With Cystic FibrosisCompletedPhase 2Galapagos NVNCT03119649Written as GLPG2222 50 mg
- A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG3067 in Healthy Subjects.CompletedPhase 1Galapagos NVNCT03128606Written as GLPG3067/GLPG2222 multiple dose
- A Study to Evaluate GLPG2222 in Ivacaftor-treated Subjects With Cystic FibrosisCompletedPhase 2Galapagos NVNCT03045523Written as GLPG2222 150 mg q.d.
- A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG2451 in Healthy Male SubjectsCompletedPhase 1Galapagos NVNCT03214614Written as GLPG2451/GLPG2222 multiple dose
- First-in-Human Single and Multiple Dose of GLPG2222CompletedPhase 1Galapagos NVNCT02662452Written as GLPG2222 single dose
Given beside what is tested · 2 — GLPG2222 is usual care or a partner of the new treatment
- A Study to Assess the Pharmacokinetics and Safety of Co-administered Oral Galicaftor, Navocaftor, and ABBV-576 in Healthy Adults for the Treatment of Cystic FibrosisCompletedPhase 1AbbVieNCT05530278Written as Galicaftor
- A Study Looking at the Safety, Tolerability and Efficacy of the Combination of the Study Drugs GLPG2451 and GLPG2222 With or Without GLPG2737 in Patients With Cystic Fibrosis.CompletedPhase 1Galapagos NVNCT03540524Written as GLPG2222